Publicou 6 edições por ano
ISSN Imprimir: 1045-4403
ISSN On-line: 2162-6502
Indexed in
New Prospectives of Prostate Cancer Gene Therapy: Molecular Targets and Animal Models
RESUMO
Prostate cancer is the most common cancer and the second leading cause of cancer-related death among North American men. The low cure rate for prostate cancer is associated with the fact that many patients have metastatic disease at the time of disease presentation. Currently available therapeutic modalities for prostate cancer, such as surgery, radiation, hormone therapy, and chemotherapy, have failed to cure patients because these therapies are not sufficiently tumor-specific, resulting in dose-limiting toxicity. Therefore, gene therapy may offer great promise in this regard. In this article, we summarize current advances in gene therapy technologies for the treatment of cancer in general, and future prospects for treatment of human prostate cancer metastasis. We specifically emphasize current studies for improvement, both in the efficiency and the specificity of viral and nonviral vectors, and restricted transgene expression in tumors, to achieve selective targeting with minimized host organ toxicity, based on the molecular understanding of potential regulatory differences between normal and tumor cells. Cell and animal models used to study prostate cancer growth, invasion, and metastasis, and their usefulness in preclinical evaluation of therapeutic vectors in the treatment of protate cancer skeletal metastasis are also discussed.
-
Chung Leland W.K., Huang Wen-Chin, Sung Shian-Ying, Wu Daqing, Odero-Marah Valerie, Nomura Takeo, Shigemura Katsumi, Miyagi Tohru, Seo Seogil, Shi Chumeng, Molitierno Joe, Elmore James, Anderson Cynthia, Isotani Shuji, Edlund Magnus, Hsieh Chia-Ling, Wang Ruoxiang, Shehata Bahig, Zhau Haiyen E., Stromal-Epithelial Interaction in Prostate Cancer Progression, Clinical Genitourinary Cancer, 5, 2, 2006. Crossref
-
Sung Shian-Ying, Chung Leland W.K., Prostate tumor-stroma interaction: molecular mechanisms and opportunities for therapeutic targeting, Differentiation, 70, 9-10, 2002. Crossref
-
Wang Ruoxiang, He Hui, Sun Xiaojuan, Xu Jianchun, Marshall Fray F., Zhau Haiyen, Chung Leland W.K., Fu Haian, He Dalin, Transcription variants of the prostate-specific PrLZ gene and their interaction with 14-3-3 proteins, Biochemical and Biophysical Research Communications, 389, 3, 2009. Crossref
-
Sung Shian-Ying, Hsieh Chia-Ling, Wu Daqing, Chung Leland W.K., Johnstone Peter A.S., Tumor Microenvironment Promotes Cancer Progression, Metastasis, and Therapeutic Resistance, Current Problems in Cancer, 31, 2, 2007. Crossref
-
Sanlioglu Ahter Dilsad, Koksal Ismail Turker, Ciftcioglu Akif, Baykara Mehmet, Luleci Guven, Sanlioglu Salih, Differential Expression of TRAIL and its Receptors in Benign and Malignant Prostate Tissues, Journal of Urology, 177, 1, 2007. Crossref
-
Aneja Ritu, Miyagi Tohru, Karna Prasanthi, Ezell Tucker, Shukla Deep, Vij Gupta Meenakshi, Yates Clayton, Chinni Sreenivasa R., Zhau Haiyen, Chung Leland W.K., Joshi Harish C., A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells, European Journal of Cancer, 46, 9, 2010. Crossref
-
Caceres Gisela, Zankina Ralitza, Zhu XiaoYun, Jiao Jin-an, Wong Hing, Aller Alex, Andreotti Peter, Determination of chemotherapeutic activity in vivo by luminescent imaging of luciferase-transfected human tumors, Anti-Cancer Drugs, 14, 7, 2003. Crossref
-
de Dios Eugenio Santos, The use of animal models in cancer research, Revista de Oncología, 4, 2, 2002. Crossref
-
Hsieh Chia-Ling, Gardner Thomas A, Miao Li, Balian Gary, Chung Leland W K, Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells, Cancer Gene Therapy, 11, 2, 2004. Crossref